Exosome Therapy for Hair

What it is

Exosomes are very small extracellular vesicles released by cells as part of cell-to-cell communication. They can contain proteins, lipids, RNA, and other biological molecules.

For hair loss, researchers are studying whether extracellular vesicles derived from sources such as mesenchymal stromal cells may influence cells involved in hair-follicle activity. These proposed mechanisms are supported largely by laboratory and preclinical research; the extent to which they translate into reliable clinical hair growth is still being studied.

Exosome treatment is not one standardized therapy. Human studies have used products derived from different tissues and cell sources, including adipose tissue, placenta, foreskin-derived stromal cells, hair follicles, bone marrow, and umbilical cord. Some studies have also evaluated non-MSC-derived extracellular-vesicle preparations.

Delivery methods also vary. Some preparations have been injected into the scalp, while others have been applied with microneedling or other techniques intended to improve delivery through the skin. These approaches should not be assumed to have the same effectiveness or safety profile.

Why people consider it

• They have androgenetic alopecia and are interested in an emerging non-surgical treatment
• They have been offered an exosome product by a clinic and want to understand how much human clinical evidence exists
• They are comparing exosome treatment with more established hair-loss treatments
• They want to understand the difference between topical or microneedling-assisted application and direct scalp injection

What the experience is like

The treatment experience depends heavily on how the product is delivered. Published studies include direct intradermal scalp injections as well as treatments combined with microneedling or other delivery methods.

There is no standardized schedule across the clinical literature. Studies differ in the amount of product used, number of sessions, treatment intervals, delivery technique, exosome source, and follow-up period.

Small clinical studies have reported improvements in measures such as hair density and hair thickness, but most studies have involved relatively small groups and limited follow-up. These findings should therefore be viewed as preliminary rather than as a predictable treatment result.

Limitations & considerations

• No exosome-based medicinal product has been formally approved in South Korea to date, and the clinical studies discussed here should not be interpreted as regulatory approval for hair-loss treatment
• Different exosome products cannot be treated as interchangeable. Biological source, purification, concentration, manufacturing standards, storage, and delivery method can all differ
• The 2025 clinical systematic review found only 11 human studies, including two randomized trials. Sample sizes were small and study designs, products, and follow-up periods varied substantially
• A positive result from one specific exosome formulation does not establish that another clinic's product will produce the same result
• Direct injection deserves particular caution. A 2025 South Korean case series documented severe and persistent inflammatory reactions after intradermal injection of unapproved exosome-containing cosmetic formulations
• The published Korean cases involved procedures performed outside medical supervision, so they do not establish the complication rate for medically supervised treatment
• Long-term safety remains insufficiently characterized because most clinical studies are recent and follow-up is limited
• No specific increase in hair density, thickness, or other outcome can be guaranteed